Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the novel IPC analog SIG-1451 may inhibit inflammatory cytokine release in cell-based assays relevant to allergic dermatitis.

This study explored the molecular mechanisms by which Polygonum multiflorum may treat androgenic alopecia, suggesting it influences cell apoptosis and inflammation through specific pathways, with potential application value pending further testing.

This case report describes a 13-year-old girl with various autoimmune symptoms successfully treated with the antibiotic and immunomodulatory drug co-trimoxazole; its potential role in autoimmune disease treatment is explored.

This study highlights that although mogamulizumab is highly effective for treating mycosis fungoides and Sézary syndrome, it frequently causes a variety of rashes as side effects.

In this case report, mogamulizumab treatment for Sézary syndrome was associated with rashes and alopecia in a patient, highlighting the potential for immune-mediated side effects and suggesting that such adverse effects might indicate a favorable prognosis, though further studies are needed.

In this study, 1% pimekrolimus cream was found to be more effective than 0.05% clobetasol propionate for treating active plaques in patients with alopecia areata.

This study reported that the combination of tacrolimus, clobetasol, and minoxidil improved hair measurements and stabilized inflammation in primary cicatricial alopecia patients, with most tolerating the treatment well.

Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.

Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.

This review discusses the potential benefits of nonantibiotic macrolides for treating inflammatory skin disorders and reports no new clinical results.

This study found that MPEG-dihexPLA micelles significantly improved the skin deposition of tacrolimus compared to a marketed ointment, suggesting better targeted delivery with reduced systemic absorption.

This study found that in an ex vivo model simulating alopecia areata, the DHODH inhibitor farudodstat reduced T-cell proliferation and MHC protein expression in hair follicles, suggesting it may protect against immune privilege collapse without cytotoxic effects.

This study reports that a combination of upadacitinib and oral minoxidil resulted in complete hair regrowth in a 20-year-old with alopecia universalis, Crohn's disease, and atopic dermatitis.

This study found that the selective PPARγ modulator GMG-43AC may inhibit unwanted hair growth by inducing catagen phase while preserving hair follicle epithelial progenitor cells, suggesting potential in anti-hirsutism therapy.

This review examines the role of thiopurines in managing inflammatory bowel diseases like ulcerative colitis and Crohn's disease, and reports no new clinical results, emphasizing the need for more studies on thiopurine withdrawal scenarios.

A woman had a severe skin reaction from the drug imiquimod, used for skin cancer, highlighting the need for awareness of rare but serious side effects.

This systematic review reported that while combining low-dose oral minoxidil with Janus kinase inhibitors may enhance treatment outcomes in alopecia areata, the evidence remains weak due to limited sample sizes and potential publication bias, and more rigorous trials are necessary to assess efficacy and safety.

This study found that coadministration of pimecrolimus may interfere with the therapeutic efficacy of mesenchymal stem cell therapy in atopic dermatitis.

Farudodstat may effectively treat alopecia areata without harmful side effects.

This study found that topical pimecrolimus is as effective as clobetasol propionate for treating alopecia areata, with better tolerability in terms of side effects.

TAK-279 effectively reduces psoriasis symptoms and is safe.

In this study, imiquimod was found to increase regression of cervical intraepithelial neoplasia compared to placebo, though it commonly caused side effects that rarely led to treatment discontinuation.

Farudodstat may help treat alopecia areata by protecting hair follicles.

In this retrospective cohort study, patients using leflunomide for primary autoimmune conditions showed a decreased risk of developing alopecia areata, while those using methotrexate, cyclosporine, and rituximab had an increased risk.

This review update suggests that mycophenolate mofetil may increase complete disease remission in proliferative lupus nephritis compared to intravenous cyclophosphamide, but with low certainty of evidence.

In this case report, researchers documented a 71-year-old woman with both alopecia areata and bullous pemphigoid who showed significant improvement using dupilumab after other treatments failed, highlighting its potential for autoimmune diseases with overlapping inflammatory mechanisms.

In this study, a patient with severe alopecia areata showed significant hair regrowth after 15 months of partial response to baricitinib and oral minoxidil, following the addition of dupilumab to their treatment regimen.

This study found that methylprednisolone can block IgG-induced keratinocyte detachment in an animal model of pemphigus vulgaris, potentially by increasing the synthesis and modifying adhesion molecules.

This case study reports that a combination of PUVA therapy and oral methyl prednisolone initially improved symptoms of a woman's cutaneous T-cell lymphoma but required ongoing treatment due to recurrence.